lung cancer

Showing 15 posts of 203 posts found.

AstraZeneca

AstraZeneca receives US approval for Iressa

July 16, 2015
Medical Communications, Sales and Marketing AstraZeneca, FDA, Iressa, lung cancer, non-small cell lung cancer

AstraZeneca’s lung cancer therapy Iressa has been approved by the FDA – four years after the company pulled it from the …

Opdivo

BMS’ Opdivo improves lung cancer survival

May 29, 2015
Research and Development, Sales and Marketing ASCO, BMS, Bristol-Myers Squibb, NSCLC, lung cancer, nivolumab, non-small cell lung cancer, opdivo

A Phase III trial of Bristol-Myers Squibb’s immunotherapy Opdivo has found it increases overall survival in people with a common …

Lilly image

German court rules against Lilly in Alimta patent case

March 10, 2015
Manufacturing and Production, Sales and Marketing ACS, Actavis, Alimta, NICE, NSCLC, lilly, lung cancer, pemetrexed

A German court has ruled that Lilly’s patent for its lung cancer drug Alimta would not be infringed by generic …

BMS image

BMS’ Opdivo wins US lung cancer race

March 5, 2015
Research and Development, Sales and Marketing BMS, Prostvac, biosciences, flexus, lung cancer, oncology, opdivo

The FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with metastatic squamous non-small cell lung cancer …

Takeda image

Takeda trial hits late-stage buffers

February 17, 2015
Research and Development, Sales and Marketing AMG 706, Japan, NSCLC, Takeda, lung cancer, motesanib

Takeda is to scrap an advanced trial of an investigational drug after it failed to show any benefit in survival …

Lung xray image

‘Postcode lottery’ still cause of many lung cancer deaths

December 3, 2014
Research and Development, Sales and Marketing DoH, Roche, astranzeneca, lung cancer, nlca, oncology, pd-1

Patients are still pointlessly dying of lung cancer due to a ‘postcode lottery’ of services according to new results from …

BI image

Boehringer’s lung cancer drug Vargatef sees EU approval

November 28, 2014
Sales and Marketing Boehringer, EU, Europe, IPF, NSCLC, lung cancer, nintedanib, ofev, vargatef

Boehringer Ingelheim’s nintedanib has received its second nod in Europe this month with the European Commission approving it for the …

Boehringer’s lung cancer drug gets EMA nod

September 29, 2014
Sales and Marketing Boehringer, IPF, docetaxel, ingelheim, lung cancer, nintedanib

The EMA has issued a positive opinion for the approval of Boehringer Ingelheim’s nintedanib in combination with docetaxel for the …

Genome-driven lung cancer trial launches

June 18, 2014
Research and Development, Sales and Marketing AstraZeneca, Cancer, Genentech, MedImmune, Pfizer, genome, lung cancer

Amgen, Genentech, Pfizer, AstraZeneca and MedImmune – AstraZeneca’s global biologics R&D arm – have each put investigative treatments into a …

boehringer image

Boehringer lung cancer drug shows survival benefit

June 3, 2014
Sales and Marketing ASCO, Boehringer, NSCLC, afatinib, giotrif, lung cancer

A new analysis of two late-stage trials shows that Boehringer drug Giotrif extends overall survival in a large proportion of …

boehringer_angle_22

Giotrif increases lung cancer survival

May 16, 2014
Research and Development, Sales and Marketing Boehringer, Iressa, Roche, Tarceva, afatinib, giotrif, lung cancer

Boehringer Ingelheim is trumpeting overall survival results from a new analysis of two late-stage studies involving Giotrif in lung cancer …

AZ image

AstraZeneca lung cancer data reveals promise

May 15, 2014
Sales and Marketing ASCO, AstraZeneca, NSCLC, azd0291, lung cancer

AstraZeneca has released promising data in a lung cancer trial with one of its investigational drugs, AZD9291, which has breakthrough …

astrazeneca_plaque

AstraZeneca begins lung cancer trial

May 9, 2014
Research and Development, Sales and Marketing AstraZeneca, Cancer, MEDI4736, NSCLC, lung cancer

AstraZeneca, currently at the centre of a £63 billion bid from US giant Pfizer, has begun a late-stage trial of …

GSK image

Lung cancer vaccine dropped

April 2, 2014
Research and Development, Sales and Marketing GSK, MAGE-A3, NSCLC, Vaccine, lung cancer, magrit

GlaxoSmithKline took a hit today after its lung cancer vaccine MAGE-A3 failed to benefit patients. The London-based firm has now …

Xalkori image

Pfizer’s Xalkori impresses in new setting

March 26, 2014
Research and Development, Sales and Marketing NHS, NICE, NSCLC, Pfizer, Xalkori, lung cancer

Pfizer’s lung cancer treatment Xalkori has proven better at treating patients in a first-line setting when compared to chemotherapy. This …

The Gateway to Local Adoption Series

Latest content